India Glycols Ltd (INDIAGLYCO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by India Glycols Ltd on NSE and BSE, with an AI summary of each filing.
Please find attached
Others (Uncategorized) · 03 Nov 2026, 4:46 am
Ennature Bio Pharma Secures BSE and NSE Listing Approvals Post-Demerger Ennature Bio Pharma Limited received listing and trading approvals from BSE and NSE on 2nd Nov'26 for 2,23,42,255 equity shares (face value Rs. 5 each), allotted pursuant to the Scheme of Arrangement involving India Glycols Limited and IGL Spirits Limited. Trading in the equity shares is scheduled to commence on 4th Nov'26 across both exchanges.
Please find attached
Others (Uncategorized) · 03 Nov 2026, 4:44 am
IGL Spirits Secures BSE and NSE Listing Approvals for 6.70 Crore Shares IGL Spirits Limited has received listing and trading approvals from BSE and NSE on 2nd Nov'26 for 6,70,26,765 equity shares of face value Rs. 5 each. The allotment and listing follow the composite Scheme of Arrangement involving India Glycols Limited (Demerged Company), Ennature Bio Pharma Limited, and IGL Spirits Limited. Trading in the newly listed equity shares of IGL Spirits Limited is scheduled to commence on 4th Nov'26.
Please find attached
Others (Uncategorized) · 11 Oct 2026, 3:32 am
India Glycols Receives GST Penalty Order of Rs 6.22 Lakh India Glycols Limited received an order dated 10th Oct'26 from the State Tax Officer, SGST Department, Uttarakhand, levying a penalty of Rs 6,22,080 under the GST Act, 2017. The penalty arose during a transit inspection where Part-B details were omitted on the E-way bill for one of three customer invoices due to transporter oversight, despite valid E-invoices and matched goods. The company deposited the penalty to release the vehicle and plans to challenge the order before the appellate forum.
Please find attached
Others (Uncategorized) · 09 Oct 2026, 9:33 pm
India Glycols Clarifies Share Price Movement as Purely Market-Driven India Glycols Limited clarified to BSE and NSE on 9th Oct'26 regarding recent share price movements, stating that no undisclosed material information, event, or announcement exists that requires disclosure under SEBI Listing Regulations. The company confirmed it is unaware of any specific internal reasons behind the price fluctuation, attributing the movement entirely to market dynamics. Management reiterated its commitment to regulatory compliance and timely disclosure of all price-sensitive developments.
The Exchange has sought clarification from India Glycols Ltd on October 08, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 09 Oct 2026, 12:34 am
Please find attached.
Others (Uncategorized) · 06 Oct 2026, 11:32 pm
India Glycols Outlines Cost Apportionment for Bio Pharma and Spirits Demergers Pursuant to the NCLT-sanctioned Scheme of Arrangement effective 1st Sep'26, India Glycols Limited completed the demerger of its Bio Pharma and Spirits & Biofuel undertakings into Ennature Bio Pharma Limited and IGL Spirits Limited, respectively. For determining post-demerger acquisition costs under tax regulations, original acquisition costs are apportioned as 31.77% to India Glycols Limited, 20.61% to Ennature Bio Pharma Limited, and 47.62% to IGL Spirits Limited. Share entitlement ratios were 1:3 for Ennature Bio Pharma and 1:1 for IGL Spirits against existing holdings as of 2nd Sep'26.
Please find attached.
Others (Uncategorized) · 06 Oct 2026, 11:24 pm
India Glycols Shifts Upcoming Analyst and Investor Meetings to Virtual Mode India Glycols Limited announced an update regarding its analyst and institutional investor meetings scheduled for 7th Oct'26 and 8th Oct'26. Pursuant to Regulation 30 of the SEBI Listing Regulations and following its prior intimation dated 1st Oct'26, the company informed stock exchanges that the format for these scheduled interactions has been shifted from in-person to virtual mode. All other details and parameters disclosed in the previous communication remain unchanged.
Please find attached.
Intimation · 01 Oct 2026, 9:44 pm
India Glycols Schedules In-Person Non-Deal Roadshow in Mumbai India Glycols Limited has scheduled an in-person Non-Deal Roadshow for analysts and institutional investors on 7th Oct'26 and 8th Oct'26 in Mumbai. Pursuant to Regulation 30 of the SEBI Listing Regulations, the company confirmed that discussions will strictly focus on publicly available information with no unpublished price-sensitive information (UPSI) being shared during the interactions.
Please find attached.
Intimation · 22 Sept 2026, 10:18 pm
India Glycols Schedules In-Person Singapore Non-Deal Roadshow India Glycols Limited has scheduled an in-person Non-Deal Roadshow for analysts and institutional investors in Singapore on 28th Sep'26 and 29th Sep'26. The company confirmed that interactions will be strictly based on publicly available information, with no unpublished price-sensitive information (UPSI) to be discussed.
Please find attached.
Others (Uncategorized) · 16 Sept 2026, 9:49 pm
India Glycols Schedules Investor and Analyst Plant Visits for Sep'26 India Glycols Limited announced under SEBI Listing Regulations that it will host a group plant visit and interaction for various investors and analysts across its Kashipur and Dehradun facilities. The scheduled visits will take place over two days, on 19th Sep'26 and 20th Sep'26. The company noted that discussions will strictly rely on publicly available information, with no unpublished price-sensitive information (UPSI) intended to be shared during the interactions.
Please find attached
Others (Uncategorized) · 09 Sept 2026, 12:39 am
Ennature Bio Pharma Approves Share Allotment and Key Appointments Under Scheme Ennature Bio Pharma Limited's board approved the allotment of 2,23,42,255 equity shares (face value INR 5 each) in a 1:3 ratio to eligible India Glycols Limited shareholders as of the 2nd Sep'26 record date under their Scheme of Arrangement. The board also approved the Information Memorandum to seek stock exchange listing and trading approvals. Additionally, Ajay Sharma was appointed Chief Financial Officer, Preeti Choudhary as Company Secretary and Compliance Officer, and key auditors were appointed on 8th Sep'26.
Please find attached
Others (Uncategorized) · 09 Sept 2026, 12:33 am
IGL Spirits Allots Equity Shares Pursuant to Scheme and Approves Listing Application IGL Spirits Limited approved the allotment of 6,70,26,765 equity shares of INR 5 each in a 1:1 ratio to eligible India Glycols Limited shareholders registered as of the 2nd Sep'26 record date under the Scheme of Arrangement. The board approved the Information Memorandum to seek stock exchange listing and trading approvals. Additionally, Naresh Kumar Agrawal was appointed as CFO & KMP, Ishan Khanna as CS & Compliance Officer, M/s MAKS & Co. as Secretarial Auditor, and M/s S.S. Kothari Mehta & CO. LLP as Internal Auditor.
Please find attached
Intimation · 08 Sept 2026, 12:29 am
India Glycols Schedules In-Person Non-Deal Roadshow in Mumbai India Glycols Limited has scheduled an in-person Non-Deal Roadshow with analysts and institutional investors on 10th Sep'26 and 11th Sep'26 in Mumbai. The company confirmed that discussions will be strictly restricted to publicly available information, with no unpublished price-sensitive information (UPSI) to be shared during the interactions.
Please find attached
Others (Uncategorized) · 08 Sept 2026, 12:09 am
India Glycols Reports Board Resignations at Ennature Bio Pharma Amid Scheme of Arrangement India Glycols Limited disclosed that three Non-Executive Directors of Ennature Bio Pharma Limited (EBL)—Manish Chandra Pant, Bhupendar Pal Singhal, and Shashi Kant Shukla—resigned due to personal reasons, effective 7th Sep'26. The update was submitted pursuant to regulatory compliance for the ongoing Scheme of Arrangement involving India Glycols, EBL, and IGL Spirits Limited, following prior observation letters issued by NSE on 17th Nov'25 and BSE on 19th Nov'25.
Please find attached
Others (Uncategorized) · 07 Sept 2026, 11:58 pm
Three Non-Executive Directors Resign from IGL Spirits Board India Glycols Limited announced that three Non-Executive Directors of IGL Spirits Limited—Manish Chandra Pant, Bhupendar Pal Singhal, and Shashi Kant Shukla—resigned from their board positions with immediate effect on 7th Sep'26 citing personal reasons. The disclosure was submitted to stock exchanges as a material regulatory update concerning the ongoing Scheme of Arrangement involving India Glycols Limited, Ennature Bio Pharma Limited, and IGL Spirits Limited.
Please find attached for Chemical Business.
Investor Presentation · 03 Sept 2026, 3:01 am
India Glycols Demerger Creates Three Entities Amid Strong Specialty Chemicals Margin Expansion India Glycols Limited executed a strategic demerger effective 1st Sep'26, creating three independent listed entities: IGL Spirits (67% FY26 net revenue share), retained IGL (28%), and Ennature Biopharma (6%). The retained IGL business, focused on bio-based specialty chemicals, reported FY26 net sales of INR 1,164 Cr. Despite revenue moderation, adjusted EBITDA reached INR 330 Cr, driving a robust margin expansion to 28.4%. Looking ahead, management targets INR 2,000 Cr net revenue and INR 400 Cr EBITDA over the next 4-5 years, driven by specialty-led portfolio development.
Please find attached for Chemical Business.
Investor Presentation · 02 Sept 2026, 10:20 pm
India Glycols Demerger: Restructuring Unlocks Value with Aggressive Bio-Chemicals Growth Targets India Glycols executed a three-way demerger effective 1st Sep'26, spinning off its Spirits and Biopharma units into independent listed companies. Investors receive one IGL Spirits share per IGL share, and one Ennature share for every three IGL shares. The retained entity focuses on bio-based specialty chemicals, reporting FY26 net sales of INR 1,164 Cr and an adjusted EBITDA of INR 330 Cr (28.4% margin). Driven by a renewable-carbon strategy, management targets INR 2,000 Cr in net revenue and INR 400 Cr EBITDA within 4-5 years.
Please find attached for Spirits and Bio Fuel.
Investor Presentation · 02 Sept 2026, 10:17 pm
IGL Spirits Targets Debt-Free Status by FY28 and ~INR 1,000Cr EBITDA by FY31 IGL Spirits Limited targets a debt-free balance sheet by FY28 and ~INR 1,000Cr EBITDA by FY31, driven by premiumizing potable spirits and scaling bio-fuels. Displaying robust historical growth, FY24-FY26 revenue and EBITDA achieved 39% and 48% CAGRs, respectively, reaching INR 2,801Cr and INR 492Cr in FY26 with a 20.5% RoCE. Growth catalysts include an estimated INR 1,450Cr bio-fuel allocation for ESY 25-26, doubling IMFL volumes by FY27, and leveraging strategic partnerships with Bacardi and Amrut across its 379 MnL annual capacity platform.
Please find attached for Ennature Bio Pharma.
Investor Presentation · 02 Sept 2026, 10:15 pm
Ennature Biopharma: FY26 Financials, Segment Mix, and Strategic Nutraceutical Expansion As of Sep'26, Ennature Biopharma (demerged from India Glycols) reported FY26 revenue of INR 246 Cr, a 40.1% gross margin, and an 11.9% EBITDA margin. The firm utilizes robust cash flows from its mature Plant-based APIs (67% of sales) to fund its high-growth, high-margin Nutraceuticals segment (17% of sales). Driven by 83% export penetration in nutraceuticals and global USFDA/EU-GMP certifications, Ennature’s strategic roadmap targets scaling to 6-8 clinically validated branded ingredients, launching one new API annually, and aggressively expanding higher-value market share across US and European health platforms.
Please find attached.
Change in Management · 02 Sept 2026, 12:18 am
India Glycols Announces Senior Management Departures Post-Restructuring India Glycols Limited announced that several Senior Management Personnel (SMPs) ceased their roles effective from the close of business hours on 31st Aug'26. This change is a direct result of the company's Scheme of Arrangement, which became effective on 1st Sep'26. The departing managers, including heads of various business units, have transferred their employment to the resulting companies created by the scheme. This move follows the planned corporate restructuring and was disclosed under SEBI's Listing Regulations.
Please find attached.
Others (Uncategorized) · 01 Sept 2026, 9:40 pm
India Glycols Announces Demerger into Three Separate Entities India Glycols Limited's demerger scheme is effective from 1st Sep'26, creating three separate listed entities. The original company retains the chemicals and glycols businesses (Jun'26 quarter revenue: ₹345 crore). Two new companies will be formed: IGL Spirits Limited (spirits, bio-fuel; ₹694 crore revenue) and Ennature Bio Pharma Limited (bio-pharma; ₹90 crore revenue). For the record date of 2nd Sep'26, shareholders will receive 1 IGL Spirits share for every 1 India Glycols share and 1 Ennature share for every 3 India Glycols shares.
Please find attached.
Intimation · 28 Aug 2026, 10:21 pm
India Glycols Schedules Analyst and Investor Meeting India Glycols Limited has scheduled a physical group meeting with analysts and institutional investors. The event will take place in Mumbai on Wednesday, 2nd Sep'26, starting from 5:00 pm IST. Per the company's disclosure, discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be shared. The schedule is subject to change based on exigencies.
Please find attached.
Others (Uncategorized) · 22 Aug 2026, 12:58 am
IGL Spirits Limited Appoints Board Following Scheme of Arrangement IGL Spirits Limited, as part of its Scheme of Arrangement with India Glycols, has constituted its new board. The appointments were approved on 21st Aug'26 and include Shri U.S. Bhartia as Chairman & MD for a five-year term. Shri Vedant Jhaver and Shri Shirish Rajendra Barwale join as Non-Executive Directors. Four Independent Directors, including Samrat Banerjee and Vimal Bhandari, were also appointed for three-year terms. The appointments are subject to shareholder approval. Shri Vedant Jhaver and Shri Shirish Barwale are sons-in-law of Shri U.S. Bhartia.
Please find attached.
Others (Uncategorized) · 22 Aug 2026, 12:56 am
Ennature Bio Pharma Announces Major Board and Management Appointments As part of a Scheme of Arrangement with India Glycols, Ennature Bio Pharma Limited appointed a new Board on 21st Aug'26. Pragya Bhartia Barwale was named Managing Director for a five-year term, having led the division to over Rs. 200 Crores in revenue. U.S. Bhartia and Pooja Jhaver join as Non-Executive Directors. Additionally, four new Independent Directors, including professionals from finance, legal, and agribusiness sectors, were appointed for three-year terms, strengthening governance and strategic oversight for the newly structured entity.
Please refer to attachment.
Others · 22 Aug 2026, 12:05 am
India Glycols Sets Record Date for Demerger and Share Allotment India Glycols (IGL) has fixed 2nd Sep'26 as the record date for its demerger into two resulting companies, following NCLT approval. The effective date for the scheme is 1st Sep'26. Eligible IGL shareholders will be allotted shares in the new entities. For every 3 shares held in IGL, shareholders will receive 1 share in Resulting Company 1 (Ennature Bio Pharma). For every 1 share held in IGL, shareholders will receive 1 share in Resulting Company 2 (IGL Spirits Limited). The new shares will be listed on BSE/NSE.